{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031410","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.541213+00:00","generated_at":"2026-06-21T23:05:47.765706+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Oncocyte Q3 revenue $1.0M (down 52% QoQ), net loss $9.3M; engages Perella Weinburg for strategic alternatives","bullets":["Total revenue $1.0M in Q3 2022 vs $2.1M prior quarter; net loss $9.3M ($0.08 per share) vs $13.8M loss ($0.15) in prior year.","DetermaRx sample volume up 51% YoY; onboards physician base +62% YoY.","Engaged Perella Weinburg Partners as advisor to evaluate strategic alternatives.","Cash, equivalents, and marketable securities $34.2M as of Sept 30, 2022.","DetermaIO sample volume from Early Adopters grew 117% QoQ."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031410","json":"https://secwatch.observer/filing/0001493152-22-031410.json","markdown":"https://secwatch.observer/filing/0001493152-22-031410.md","text":"https://secwatch.observer/filing/0001493152-22-031410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222031410/0001493152-22-031410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222031410/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:05:47.765706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"955ef3671281d37b142909858ed8d78fc4a67357","claim":"Insight Molecular Diagnostics Inc. reported the three and nine months ended September 30, 2022 results: revenue $1.0 million, net income $9.3 million, EPS $0.08.","evidence_excerpt":"from the past few years transition to market launches of several new high-value, reimbursed tests over coming quarters.” Third Quarter 2022 Financial Results Total revenue was $1.0 million for the third quarter of 2022, compared to $2.1 million for the prior quarter. Third quarter revenues associated with DetermaRx were $1.0 million, an increase of $0.1 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222031410/0001493152-22-031410-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2022"},{"label":"Revenue","value":"$1.0 million"},{"label":"Net income","value":"$9.3 million"},{"label":"EPS","value":"$0.08"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}